These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 25926282)

  • 21. Cost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis.
    Soini EJ; Hallinen TA; Puolakka K; Vihervaara V; Kauppi MJ
    J Med Econ; 2012; 15(2):340-51. PubMed ID: 22168785
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Understanding and improving the one and three times GDP per capita cost-effectiveness thresholds.
    Robinson LA; Hammitt JK; Chang AY; Resch S
    Health Policy Plan; 2017 Feb; 32(1):141-145. PubMed ID: 27452949
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness analysis in a setting of budget constraints--is it equitable?
    Ubel PA; DeKay ML; Baron J; Asch DA
    N Engl J Med; 1996 May; 334(18):1174-7. PubMed ID: 8602185
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Benefit adequacy among elderly Social Security retired-worker beneficiaries and the SSI federal benefit rate.
    Rupp K; Strand A; Davies P; Sears J
    Soc Secur Bull; 2007; 67(3):29-51. PubMed ID: 18605217
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-benefit and cost-effectiveness analysis for health promotion programs.
    Barry PZ; DeFriese GH
    Am J Health Promot; 1990; 4(6):448-52. PubMed ID: 10113240
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacoeconomic concepts in antiplatelet therapy: understanding cost-effectiveness analyses using clopidogrel as an example.
    Weintraub WS
    J Cardiovasc Pharmacol Ther; 2008 Jun; 13(2):107-19. PubMed ID: 18495905
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combining Time-Driven Activity-Based Costing with Clinical Outcome in Cost-Effectiveness Analysis to Measure Value in Treatment of Depression.
    El Alaoui S; Lindefors N
    PLoS One; 2016; 11(10):e0165389. PubMed ID: 27798655
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stochastic league tables: an application to diabetes interventions in the Netherlands.
    Hutubessy RC; Niessen LW; Dijkstra RF; Casparie TF; Rutten FF
    Health Econ; 2005 May; 14(5):445-55. PubMed ID: 15386648
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Needs-based sewerage prioritization: alternative to conventional cost-benefit analysis.
    Rashid MM; Hayes DF
    J Environ Manage; 2011 Oct; 92(10):2427-40. PubMed ID: 21624766
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A proposed cost effectiveness method for use in policy formulation in human service organizations.
    Holosko MJ; Dobrowolsky J; Feit MD
    J Health Soc Policy; 1990; 1(3):55-71. PubMed ID: 10113664
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost effectiveness. How should it be determined?
    Beaves RG; Joseph H; Rohrer JE; Zeitler RR
    Eval Health Prof; 1988 Jun; 11(2):213-30. PubMed ID: 10312609
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The CE plane: a graphic representation of cost-effectiveness.
    Black WC
    Med Decis Making; 1990; 10(3):212-4. PubMed ID: 2115096
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis.
    Stinnett AA; Mullahy J
    Med Decis Making; 1998; 18(2 Suppl):S68-80. PubMed ID: 9566468
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost analyses approaches in medical education: there are no simple solutions.
    Walsh K; Levin H; Jaye P; Gazzard J
    Med Educ; 2013 Oct; 47(10):962-8. PubMed ID: 24016166
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Use of Economic Evaluation to Inform Newborn Screening Policy Decisions: The Washington State Experience.
    Grosse SD; Thompson JD; Ding Y; Glass M
    Milbank Q; 2016 Jun; 94(2):366-91. PubMed ID: 27265561
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness and value of information analysis of nutritional support for preventing pressure ulcers in high-risk patients: implement now, research later.
    Tuffaha HW; Roberts S; Chaboyer W; Gordon LG; Scuffham PA
    Appl Health Econ Health Policy; 2015 Apr; 13(2):167-79. PubMed ID: 25650349
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries.
    Oostenbrink JB; Rutten-van Mölken MP; Monz BU; FitzGerald JM
    Value Health; 2005; 8(1):32-46. PubMed ID: 15841892
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Economic aspects of clinical decision making: applications in patient care.
    Oster G
    Am J Hosp Pharm; 1988 Mar; 45(3):543-7. PubMed ID: 3130753
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Economic outcomes of eszopiclone treatment in insomnia and comorbid major depressive disorder.
    Snedecor SJ; Botteman MF; Schaefer K; Sarocco P; Barry N; Pickard AS
    J Ment Health Policy Econ; 2010 Mar; 13(1):27-35. PubMed ID: 20571180
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Regression methods for covariate adjustment and subgroup analysis for non-censored cost-effectiveness data.
    Willan AR; Briggs AH; Hoch JS
    Health Econ; 2004 May; 13(5):461-75. PubMed ID: 15127426
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.